

12 February 2020

## Investment Objective

The investment objective of the Fund is to provide exposure to publicly-listed companies that are involved in the medical cannabis and cannabis-related life sciences industry. The Rize Medical Cannabis and Life Sciences UCITS ETF (the "Fund") aims to track the performance of the Foxberry Medical Cannabis & Life Sciences Net Return Index (the "Index") using full replication.

Share Class: USD Accumulating ETF (the "Share Class")

## Key Features

### Favourable Growth Prospects

FLWR is Europe's truly global medical cannabis ETF, and provides investors with exposure to the global revolution in cannabis-derived medication and wellness products.

ETF	·	·	·	·	·	·	·	Rize Medical Cannabis and Life Sciences UCITS ETF	·	·	·	·	·
Index Name	·	·	·	·	·	·	·	Foxberry Medical Cannabis & Life Sciences Index	·	·	·	·	·
Fund Size (AUM)	·	·	·	·	·	·	·	\$1,007,070	·	·	·	·	·
TER	·	·	·	·	·	·	·	0.65%	·	·	·	·	·

### Powered by New Frontier Data®

FLWR is purpose-built in collaboration with New Frontier Data, independent cannabis research and tech-driven analytics firm based in Washington, D.C., and leverages their unique insights and proprietary classification system of companies that have demonstrable exposure to the emerging medical cannabis and life sciences sector.

Base currency	·	·	·	·	·	·	·	USD	·	·	·	·	·
Inception Date	·	·	·	·	·	·	·	12 February 2020	·	·	·	·	·
Replication	·	·	·	·	·	·	·	Physical - Full Replication	·	·	·	·	·
UCITS	·	·	·	·	·	·	·	Yes	·	·	·	·	·
ISIN	·	·	·	·	·	·	·	IE00BJXRZ273	·	·	·	·	·

### Unconstrained Approach

FLWR's composition transcends classic sector, size and geographic classifications by tracking an emerging theme.

Listing and Tickers	·	·	·	·	·	·	·	London Stock Exchange FLWR (USD), FLWG (GBP)	·	·	·	·	·
Index Ticker	·	·	·	·	·	·	·	FXBYFLWR Index	·	·	·	·	·
Share Class	·	·	·	·	·	·	·	USD Accumulating ETF	·	·	·	·	·
Exposure	·	·	·	·	·	·	·	Global Equities	·	·	·	·	·

### ETF Efficiency

In a single trade, FLWR delivers access to dozens of companies that are favourably positioned to ride the tailwinds of the medical cannabis and life sciences theme

Domicile	·	·	·	·	·	·	·	Ireland	·	·	·	·	·
Fund Type	·	·	·	·	·	·	·	Irish ICAV	·	·	·	·	·
Issuer	·	·	·	·	·	·	·	Rize UCITS ICAV	·	·	·	·	·
Promoter	·	·	·	·	·	·	·	Rize ETF Limited	·	·	·	·	·
Manager/Investment Manager	·	·	·	·	·	·	·	Davy Global Fund Management Limited	·	·	·	·	·
Depository/Custodian	·	·	·	·	·	·	·	Northern Trust Fiduciary Services (Ireland) Limited	·	·	·	·	·


## Index Description

The Index is designed to provide exposure to publicly-traded companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors, but excluding companies that are determined to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market. Companies are only included in the Index if they are listed on one or more of the eligible stock exchanges listed in the Index Methodology. All companies classified as Big Pharma (as defined in the Index Methodology) are given a group weight of 10% and the relevant companies are equally-weighted within that. All other companies are liquidity-weighted subject to an individual company weight cap of 15%, with any excess weight being distributed across such companies in proportion to their initial weights.

The Index shall be rebalanced on a semi-annual basis in March and September in accordance with the weighting methodology described

above. It is possible that additional companies not presently represented in the Index will be added and that one or more companies presently represented will be removed at the time of the March and September rebalance dates. However, the Index also implements a conditional monthly rebalance in circumstances where a constituent's sector classification has been re-allocated to the "cultivation and retail" sector, in which instance the Index is rebalanced in accordance with the selection and weighting methodology described above with the result that the relevant company is removed from the Index and its weight is re-distributed amongst the rest of the constituents in accordance with the weighting methodology described above.

Investors should note that the respective weights of each of the constituents of the Index are expected to fluctuate in-between the periodic rebalance dates of the Index. Please see the Prospectus section entitled "Circumstances where the weighting of an Index constituent exceeds the applicable concentration limits prescribed by the UCITS Regulations" for details of the procedure to be adopted when the weighting of any constituent of the Index exceeds the permitted investment restrictions.



## Trading Information


Exchange	Currency	ISIN	Sedol	Ticker	Bloomberg Code
London Stock Exchange	USD	IE00BJXRZ273	BJXRZC7	FLWR	FLWR LN
London Stock Exchange	GBP	IE00BJXRZ273	BK5TNN5	FLWG	FLWG LN
Borsa Italiana	EUR	IE00BJXRZ273	BJXRZ38	FLWR	FLWR IM
Deutsche Borse	EUR	IE00BJXRZ273	BKPCCR1	BLUM	BLUM GY

## Top 10 Fund Holdings %

GW PHARMACEUTICALS-ADR	16.19%	Biotechnology/Pharma	58.2%
SCOTTS MIRACLE-A	15.91%	Agriculture Tech & Supplies	15.9%
ARENA PHARMACEUTICALS INC	15.61%	Hemp & Cbd	14.8%
CARA THERAPEUTICS INC	14.34%	Big Pharma	10.8%
NEW AGE BEVERAGES CORP	5.66%		
ZYNERBA PHARMACEUTICALS INC	4.45%		
AMYRIS INC	4.34%		
TEVA PHARMACEUTICAL-SP ADR	4.21%		
CHARLOTTE'S WEB HOLDINGS INC	3.96%		
CORBUS PHARMACEUTICALS HOLDINGS INC.	3.55%		

**\*\* Top 10 Fund Holding and Fund Sector Weights are as at 12/02/2020 \*\***

## Top 10 Countries




Totals may not sum to 100% due to rounding

## Investment Team

Davy Global Fund Management Limited is the investment manager for each of the exchange-traded funds (ETFs) issued by Rize UCITS ICAV and is responsible for the day-to-day investment management decisions for this ETF. The team is highly experienced to all aspects relating to the management of a fund portfolio, including the execution of equities, foreign exchange and cash management.

## Country Registration



## Risk Factors

- All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.
- FLWR is vulnerable to cyclical declines in the cannabis sector.
- Any change to existing applicable laws or regulations that currently enable companies to engage in cannabis-related business activities ("**CRB Activities**") would reduce the value of affected companies and FLWR.
- Also, some companies may breach such applicable laws or regulations which may (1) cause them to be de-listed from stock exchanges and/or reduce their market value (and therefore reduce FLWR's value or its ability to realise its investments) and/or (2) mean that capital gains or income derived from such companies cause FLWR and/or FLWR's investors to be in breach of anti-money laundering laws or other laws applicable to them respectively ("**Applicable Laws**").
- FLWR may have exposure to the recreational consumer market for cannabis even though it does not intend to. This might mean that the capital gains or income derived from companies with this exposure cause FLWR and/or FLWR's investors to be in breach of Applicable Laws.
- A change in any legal requirements relating to funds with cannabis exposure might require the Manager to stop marketing FLWR in certain countries, de-list FLWR's Shares from certain stock exchanges; and/or close FLWR.
- FLWR invests in pharmaceutical companies which may never generate revenue due to clinical trial failures and/or a lack of required approvals for new drugs. Such factors could severely reduce the values of affected companies and FLWR. FLWR also invests in small publicly traded companies which may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies.
- FLWR invests in global equity securities. As such there is a risk of loss arising from exchange rate fluctuations or exchange control regulations.
- Other: (1) Third party service providers (such as the ICAV's depositary) may go bankrupt and fail to pay money due to FLWR or return property belonging to FLWR. (2) If the Index provider stops calculating the Index or if FLWR's license to replicate the Index is terminated, FLWR may have to be closed. (3) It may not always be possible to buy and sell FLWR's Shares on a stock exchange or at prices closely reflecting the Net Asset Value. (4) There is no capital guarantee or protection on the value of FLWR and investors can lose all the capital invested in FLWR. (5) Please refer to the "Risk Factors" section of the ICAV's Prospectus and the Fund Supplement.

## Disclaimer

This document is issued by Rize ETF Limited ("**Rize**"). Rize is an Appointed Representative of Aldgate Advisors Limited, a firm authorised and regulated by the Financial Conduct Authority (FCA FRN 763187). Rize is registered in England and Wales number 11770079.

The information contained in this document is solely intended for **professional investors** as defined within the meaning of the Markets in Financial Instruments Directive (MiFID) (the "**Directive**"). Persons who do not fall within any of these definitions should return this document immediately to Rize ETF Limited ("**Rize**") and should not review the remainder of the material, and in any event, must not act or rely upon the information contained in this document. By continuing to review this document, each person is deemed to confirm, warrant and represent that they fit within the definition of per-se professional investor within the meaning of the Directive.

This document is not being provided to you on the basis that you are a client of Rize. Rize is not acting on your behalf and is not responsible for providing protections that would otherwise be afforded to clients of Rize. This document is for information purposes only. Its contents, and the fact of its distribution, do not constitute investment advice, nor do they constitute tax, legal or any other form of advice. It does not constitute or form part of any offer to issue or sell, or the solicitation of any offer to buy or sell any investment. It shall not form the basis of, or be relied upon in connection with, any contract. Where this document contains past performance and projected performance information and it must be noted that past performance and projected performance is not a reliable indicator of future results.

**Capital at Risk Warning** – An investment in the Funds involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. The products referred to in this document are offered by Rize UCITS ICAV (the "**ICAV**"). The ICAV is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with variable capital and segregated liability between its sub-funds (each, a "**Fund**") and registered in Ireland with registration number C193010 and authorised by the Central Bank of Ireland as a UCITS. The ICAV is managed by Davy Global Fund Management Limited.

The Funds are not offered or aimed at residents in any country in which (a) the ICAV and the Funds are not authorised or registered for distribution and where to do so is contrary to the relevant country's securities laws, (b) the dissemination of information relating to the ICAV and the Funds via the internet is forbidden, and/or Rize is not authorised or qualified to make such offer or invitation.

The Funds may be registered or otherwise approved for distribution to the public in one or more European jurisdictions. The fact of such a registration or approval, however, does not mean that any regulator (including the FCA) has determined that the Funds (or any share classes thereof (each, a "**Share Class**")) are suitable for all investors. Investors should continue to consider the terms of investment in any Fund (or Share Class thereof) carefully and seek professional investment advice before taking any decision to invest in such Fund (or Share Class thereof).

**United Kingdom:** For the purposes of the United Kingdom Financial Services and Markets Act 2000 ("**FSMA**"), the ICAV is a UCITS that has been recognised by the Financial Conduct Authority (the "**FCA**"). Copies of the Fund Documents (including the KIID in English language) are available on [www.rizeetf.com](http://www.rizeetf.com).

This document and its contents are not directed at any person that is resident in the United States ("**US person**"), and no offer or invitation is made to any US person to acquire or sell any service, product or security referred to. The provision of any information in this document does not constitute an offer to US persons to purchase securities.

Further information about the Funds (and Share Classes thereof) described in this document, such as details of the key underlying investments of the Funds and share prices, is available at <http://www.rizeetf.com> or from your broker or financial adviser. The indicative intra-day net asset values of the Share Classes of the Funds are available at <http://www.sofactive.com>. A UCITS ETF's units / shares that have been acquired on the secondary market cannot usually be sold directly back to the UCITS ETF itself. Investors who are not Authorised Participants must buy and sell shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees and additional taxes in doing so. In addition, as the market price at which the Shares are traded on the secondary market may differ from the Net Asset Value per Share, investors may pay more than the then current Net Asset Value per Share when buying shares and may receive less than the current Net Asset Value per Share when selling them. Any decision to invest must be based solely on the information contained in the ICAV's Prospectus, Key Investor Information Document and the latest half-yearly report and unaudited accounts and/or annual report and audited accounts. Investors should read the fund specific risks in the Key Investor Information Document and the ICAV's Prospectus.



**rizeetf.com**

**+353 1 648 1471**

**info@rizeetf.com**

Dashwood House

Old Broad Street

London EC2M 1QS